BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2529993)

  • 1. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
    Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
    Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F; Roscher R; Beger HG
    Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
    Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
    Safi F; Roscher R; Beger HG
    Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
    Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
    Wu JT
    Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V; Petrtýl J; Klener P; Chmel J
    Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.